Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?
Publication
, Journal Article
Ayala-Peacock, DN; Chino, JP
Published in: Cancer
July 1, 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Cancer
DOI
EISSN
1097-0142
Publication Date
July 1, 2023
Volume
129
Issue
13
Start / End Page
1962 / 1965
Location
United States
Related Subject Headings
- Uterine Cervical Neoplasms
- Standard of Care
- Radiotherapy, Intensity-Modulated
- Radiotherapy Planning, Computer-Assisted
- Radiotherapy Dosage
- Radiation Injuries
- Oncology & Carcinogenesis
- Humans
- Female
- Cisplatin
Citation
APA
Chicago
ICMJE
MLA
NLM
Ayala-Peacock, D. N., & Chino, J. P. (2023). Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer? Cancer, 129(13), 1962–1965. https://doi.org/10.1002/cncr.34769
Ayala-Peacock, Diandra N., and Junzo P. Chino. “Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?” Cancer 129, no. 13 (July 1, 2023): 1962–65. https://doi.org/10.1002/cncr.34769.
Ayala-Peacock DN, Chino JP. Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer? Cancer. 2023 Jul 1;129(13):1962–5.
Ayala-Peacock, Diandra N., and Junzo P. Chino. “Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?” Cancer, vol. 129, no. 13, July 2023, pp. 1962–65. Pubmed, doi:10.1002/cncr.34769.
Ayala-Peacock DN, Chino JP. Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer? Cancer. 2023 Jul 1;129(13):1962–1965.
Published In
Cancer
DOI
EISSN
1097-0142
Publication Date
July 1, 2023
Volume
129
Issue
13
Start / End Page
1962 / 1965
Location
United States
Related Subject Headings
- Uterine Cervical Neoplasms
- Standard of Care
- Radiotherapy, Intensity-Modulated
- Radiotherapy Planning, Computer-Assisted
- Radiotherapy Dosage
- Radiation Injuries
- Oncology & Carcinogenesis
- Humans
- Female
- Cisplatin